The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
Over the past decade, China's innovative drug market has experienced remarkable transformation and growth. With the combined drive of policies, technology, and capital, China's innovative drug industry has entered a golden period of growth. This paper pro